Positive recommendations have been made for PBS listings of risdiplam for Spinal Muscular Atrophy (SMA) and ofatumumab for multiple sclerosis, by the Pharmaceutical Benefits Advisory Committee (PBAC). At its March 2021 meeting the PBAC recommended PBS listing of risdiplam (Evrysdi) for patients with SMA Types 1, 2 or 3a who are aged 18 years or ...
Treatments for SMA and MS approved for PBS listing
By Michael Woodhead
29 Apr 2021